BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

10702	Companies
228922	Keywords
157518	Articles
121518	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 07/06/2026 at 09:10, 3 days 5 hours ago

BioNxt Progresses with Sublingual Semaglutide ODF Development

Drug Delivery Pharmaceutical Development BioNxt Solutions Sublingual ODF GLP-1 Therapeutics
PRESS RELEASE

published on 07/06/2026 at 09:05, 3 days 5 hours ago

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
BioNxt Solutions Inc. announces progress in Semaglutide oral dissolvable film program for GLP-1 therapies, expanding into a rapidly growing pharmaceutical market

BioNxt Solutions Inc. Pharmaceutical Market Oral Dissolvable Film GLP-1 Therapies Semaglutide
BRIEF

published on 06/23/2026 at 23:25, 15 days 15 hours ago

BioNxt Solutions Completes $2M Non-brokered Private Placement

Private Placement Securities Warrants Investments BioNxt Solutions
PRESS RELEASE

published on 06/23/2026 at 23:20, 15 days 15 hours ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. closes non-brokered private placement of units, plans to use proceeds for research and operations in Europe. Company updates on unsecured convertible debentures extension

Private Placement BioNxt Solutions Inc. Debt Extension European Research Bioscience Innovator
BRIEF

published on 06/15/2026 at 09:50, 24 days 4 hours ago

BioNxt Advances Commercialization for Patented Multiple Sclerosis Treatment

Business Development Multiple Sclerosis Cladribine BioNxt Solutions BNT23001
PRESS RELEASE

published on 06/15/2026 at 09:45, 24 days 4 hours ago

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
BioNxt Solutions Inc. partners with a BD&L advisor to commercialize BNT23001, a sublingual Cladribine ODF for MS. Preparing for a human bioavailability study

BioNxt Solutions Inc. Commercialization BNT23001 Bioavailability Study BD&L Advisor
BRIEF

published on 06/12/2026 at 23:20, 26 days 15 hours ago

BioNxt Solutions Inc. Announces Private Placement Initiative

Private Placement Stock Warrants BioNxt Solutions R&D Funding European Operations
PRESS RELEASE

published on 06/12/2026 at 23:15, 26 days 15 hours ago

BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. announces non-brokered private placement of units at $0.33 per Unit with maximum gross proceeds of $2,000,000. Offering includes common shares and purchase warrants

Private Placement Common Shares BioNxt Solutions Inc. LIFE Offering Purchase Warrants
BRIEF

published on 06/11/2026 at 00:35, 28 days 13 hours ago

BioNxt Solutions Inc. Extends Convertible Debentures and Issues Warrants

Warrants Convertible Debentures Regulatory Approval Securities Legislation BioNxt Solutions
PRESS RELEASE

published on 06/11/2026 at 00:30, 28 days 14 hours ago

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces amendment of terms for unsecured convertible debentures, extending maturity dates and issuing common share purchase warrants. For further details, visit bionxt.com

BioNxt Solutions Inc. Common Share Purchase Warrants Regulatory Approvals Debentures Maturity Dates

Accesswire

Published on 07/09/2026 at 14:00, 30 minutes ago

Corporate Update
Published on 07/09/2026 at 14:00, 30 minutes ago

GameSquare Signs Dairy MAX as Brand Partner for the World of Dance
Published on 07/09/2026 at 14:00, 30 minutes ago

Horizon Aircraft Selects BETA Technologies Advanced Flight Control Computers and Software for the Cavorite X7
Published on 07/09/2026 at 14:00, 30 minutes ago

Loop Industries Announces Date for First Quarter Fiscal 2027 Financial Results and Conference Call
Published on 07/09/2026 at 14:00, 30 minutes ago

Hillcrest Energy Technologies Signs Letter of Intent with Equipmake to Integrate ZVS Technology into Electric Powertrain Platform

View all ACCESSWIRE

EQS Group

Published on 07/09/2026 at 14:05, 25 minutes ago

DJI Puts Drones to the Test on the World's Highest Peak, Advancing Critical High-Altitude Delivery, Mapping, and Climate Research Applications
Published on 07/09/2026 at 12:35, 1 hour 55 minutes ago

Cognizant to scale to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators
Published on 07/09/2026 at 12:34, 1 hour 56 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 07/09/2026 at 12:30, 2 hours ago

Immunic to Participate in Investor Conferences in July
Published on 07/09/2026 at 12:16, 2 hours 14 minutes ago

Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation

Les Echos

Published on 07/09/2026 at 13:56, 33 minutes ago

Statement of transactions in own shares from July 6, 2026 to July 8, 2026
Published on 07/09/2026 at 07:30, 7 hours ago

Half-year liquidity contract statement June 30, 2026
Published on 07/09/2026 at 07:30, 7 hours ago

Half-year liquidity contract statement June 30, 2026
Published on 07/08/2026 at 18:30, 20 hours ago

Suspension of the liquidity contract
Published on 07/08/2026 at 18:00, 20 hours 30 minutes ago

€464 MILLION OF NEW FINANCING TO SUPPORT FREY'S GROWTH

View all LES ECHOS COMFI WIRE